Holocarboxylase synthetase deficiency

biotin structure

Holocarboxylase Synthetase Deficiency is a rare inherited disorder affecting the body's ability to break down proteins properly. This condition is classified under the broader category of organic acidemias, which are metabolic disorders characterized by an accumulation of toxic organic acids in the body. Holocarboxylase synthetase deficiency specifically impairs the body's ability to use biotin, a vitamin that plays a critical role in the metabolism of fats, proteins, and carbohydrates.

Causes and Genetics

Holocarboxylase synthetase deficiency is caused by mutations in the HLCS gene, which provides instructions for making an enzyme called holocarboxylase synthetase. This enzyme is essential for attaching biotin to certain proteins, a process necessary for their activation. Without functional holocarboxylase synthetase, these proteins cannot participate in crucial metabolic pathways, leading to the accumulation of harmful substances in the body.

The disorder is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected. Parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene but typically do not show signs and symptoms of the condition.

Symptoms

Symptoms of holocarboxylase synthetase deficiency can appear within the first few days or weeks of life and may include:

• Hypotonia (reduced muscle tone)
• Seizures
• Skin rash
• Alopecia (hair loss)
• Feeding difficulties
• Lethargy
• Developmental delay
• Metabolic acidosis, a condition marked by an increase in acid levels in the blood and body tissues

If left untreated, holocarboxylase synthetase deficiency can lead to coma and potentially death. However, early diagnosis and treatment can significantly improve the outcome for affected individuals.

Diagnosis

Diagnosis of holocarboxylase synthetase deficiency typically involves:

• Blood tests to measure levels of organic acids, which are often elevated in affected individuals
• Genetic testing to identify mutations in the HLCS gene
• Enzyme activity assays to assess the function of holocarboxylase synthetase

Treatment

The primary treatment for holocarboxylase synthetase deficiency is supplementation with high doses of biotin, which can help restore the function of biotin-dependent enzymes. Most affected individuals respond well to biotin therapy, with significant improvement in symptoms. It is crucial to start treatment as early as possible to prevent or minimize damage caused by the accumulation of toxic substances.

Prognosis

With early diagnosis and appropriate treatment, individuals with holocarboxylase synthetase deficiency can lead relatively normal lives. However, the long-term outlook varies depending on the severity of the condition and the age at which treatment is initiated. Regular follow-up with healthcare providers is essential to monitor the condition and adjust treatment as necessary.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian